Sumitomo Pharma revises forecasts up after Asia business sale

Sumitomo Pharma Co. finalized a gain of JPY 49,043 million from the sale of shares in subsidiaries, an increase from the previously estimated JPY 45 billion. This gain resulted from the absorption-type company split of its Asia business and the subsequent transfer of 60% of the new company's shares to Marubeni Global Pharma Corporation.

This finalized gain, along with strong sales of ORGOVYX and GEMTESA in North America, led Sumitomo Pharma to revise its consolidated financial forecasts for the fiscal year ending March 31, 2026. The revised forecasts include a JPY 74,000 million increase in revenue to JPY 429,000 million and a JPY 52,000 million increase in net profit attributable to owners of the parent to JPY 92,000 million. Core operating profit is also projected to rise by JPY 41,000 million to JPY 97,000 million.

The company's sales and R&D expenses saw reductions due to business restructuring and the realignment of its regenerative medicine and cell therapy business. Additionally, the Asia segment experienced decreased revenue as two subsidiaries ceased to be consolidated following the business transfer.